Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL5875869 | 1.00 | P2RY2 (0.65) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL5875823 | 1.00 | P2RY2 (0.65) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| SCHEMBL5068300 | 0.93 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2352660 | 0.91 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2346632 | 0.91 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622268 | 0.91 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622267 | 0.91 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL28456453 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL28898119 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL29482406 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2940030-B1 | METHOD FOR PRODUCING P1,P4-DI(URIDINE 5'-)TETRAPHOSPHATE | YAMASA CORP (JP) | 2017-06-14 | — | — | EP | claimed |
| EP-2045257-B1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | YAMASA CORP (JP) | 2016-08-17 | — | — | EP | claimed |
| EP-1428538-B1 | ECTOCORNEA EXTENSION PROMOTERS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-08-14 | — | — | EP | claimed |
| US-7109181-B2 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | claimed |
| US-6984629-B2 | Ectocornea extension promoters | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-01-10 | — | — | US | claimed |
| US-6921755-B2 | Method of treating dry eye disease with purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-07-26 | — | — | US | claimed |
| US-6916794-B2 | Method of enhancing drainage of lacrimal system with purinergic receptor agonists | INSPIRE PHARMACEUTICAL, INC. (US) | 2005-07-12 | — | — | US | claimed |
| JP-2005508297-A | — | — | 2005-03-31 | — | — | JP | claimed |
| EP-1428538-A1 | ECTOCORNEA EXTENSION PROMOTERS | Santen Pharmaceutical Co., Ltd (JP) | 2004-06-16 | — | — | EP | claimed |
| EP-1012154-B1 | SALTS OF DI(URIDINE 5'-TETRAPHOSPHATE), METHOD FOR PREPARATION AND USES THEREOF | INSPIRE PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | claimed |
| US-6703376-B2 | ADMINISTERING TO THE AIRWAYS OF THE PATIENT A URIDINE PHOSPHATE SUCH AS URIDINE 5'TRIPHOSPHATE OR DI(URIDINE5') TETRAPHOSPHATE FOR PROMOTING DRAINAGE OF MUCOUS SECRETIONS IN THE CONGESTED AIRWAYS OF A BEDRIDDEN/IMMOBILIZED PATIENT | INSPIRE PHARMACEUTICALS, INC. | 2004-03-09 | — | — | US | claimed |
| US-6696425-B2 | STIMULATING TEAR SECRETION AND MUCIN PRODUCTION IN EYES OF A SUBJECT BY ADMINISTERING CERTAIN URIDINE, ADENINE, OR CYTIDINE TRIPHOSPHATES AS WELL AS OTHER DINUCLEOSIDE POLYPHOSPHATE COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | claimed |
| US-20030186927-A1 | Ectocornea extension promoters | MERCK SHARP & DOHME LLC | 2003-10-02 | — | — | US | claimed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2003000056-A1 | JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6462028-B2 | P2Y2 AND/OR P2Y4 PURINERGIC RECEPTOR AGONISTS E.G., NUCLEOTIDES OF ADENOSINE, CYTIDINE AND URIDINE, DINUCLEOTIDES AND ANALOGS; TREATING VAGINAL DRYNESS ASSOCIATED WITH MENOPAUSE, CHEMOTHERAPY, AND DISEASES; VULVAR PAIN | INSPIRE PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| EP-1043329-B1 | CRYSTAL OF DIURIDINE TETRAPHOSPHATE OR SALT THEREOF AND METHOD FOR PREPARING THE SAME, AND METHOD FOR PRODUCING SAID COMPOUND | YAMASA CORP (JP) | 2002-08-28 | — | — | EP | claimed |
| US-20020103157-A1 | Method of treating dry eye disease with purinergic receptor agonists | MERCK SHARP & DOHME CORP. | 2002-08-01 | — | — | US | claimed |
| US-20020065244-A1 | Method of treating dry eye disease with purinergic receptor agonists | MERCK SHARP & DOHME CORP. | 2002-05-30 | — | — | US | claimed |
| US-10786526-B2 | Aqueous ophthalmic solution | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-10632139-B2 | Ophthalmic solution comprising diquafosol | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20190209599-A1 | AQUEOUS OPHTHALMIC SOLUTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-07-11 | — | — | US | disclosed |
| US-10278985-B2 | Aqueous ophthalmic solution | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-05-07 | — | — | US | disclosed |
| EP-3431092-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | Santen Pharmaceutical Co., Ltd. (JP) | 2019-01-23 | — | — | EP | disclosed |
| US-20180353531-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-2832359-B1 | DIQUAFOSOL-CONTAINING EYE DROP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20170348344-A1 | AQUEOUS OPHTHALMIC SOLUTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9486529-B2 | Ophthalmic solution comprising diquafosol | SANTEN PHARMCEUTICAL CO., LTD. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2614838-B1 | DIQUAFOSOL AND HYALURONIC ACID OR SALTS THEREOF FOR THE TREATMENT OF DRY EYE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150072951-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-03-12 | — | — | US | disclosed |
| EP-2832359-A1 | DIQUAFOSOL-CONTAINING EYE DROP | Santen Pharmaceutical Co., Ltd (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20140221306-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL, METHOD FOR PRODUCING THE SAME, AND METHOD FOR INHIBITING FORMATION OF INSOLUBLE PRECIPITATE | SANTEN PHARMACEUTICAL CO. LTD (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2014103704-A1 | METHOD FOR PRODUCING P1,P4-DI(URIDINE 5'-)TETRAPHOSPHATE | ヤマサ醤油株式会社 (JP) | 2014-07-03 | — | — | WO | disclosed |
| EP-2659894-A1 | OPHTHALMIC SOLUTION CONTAINING DIQUAFOSOL, METHOD FOR PRODUCING SAME, AND METHOD FOR PREVENTING FORMATION OF INSOLUBLE PRECIPITATE | Santen Pharmaceutical Co., Ltd (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1428538-B1 | ECTOCORNEA EXTENSION PROMOTERS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8097600-B2 | Method of increasing tear production with purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-7432252-B1 | Method of promoting cervical and vaginal secretions | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080214490-A1 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-7109181-B2 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060009415-A1 | Corneal epithelial migration promoter | NAKATA KATSUHIKO | 2006-01-12 | — | — | US | disclosed |
| US-6984629-B2 | Ectocornea extension promoters | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-01-10 | — | — | US | disclosed |
| CN-1228053-C | Eye drop containing diuridine phosphoric acid | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| US-6864243-B1 | Method for treating retinal degeneration with purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20050009778-A1 | Method for treating retinal degeneration with purinergic receptor agonists | PETERSON WARD M (US) | 2005-01-13 | — | — | US | disclosed |
| US-6765090-B2 | DRUGS; STABILITY, SOLUBILITY, NONTOXIC, EASY TO HANDLE | INSPIRE PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1428538-A1 | ECTOCORNEA EXTENSION PROMOTERS | Santen Pharmaceutical Co., Ltd (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6713458-B1 | DRY EYE; RETINAL DETACHMENT | INSPIRE PHARMACEUTICALS, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20040058926-A1 | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | PHARMACIA CORPORATION | 2004-03-25 | — | — | US | disclosed |
| US-6703376-B2 | ADMINISTERING TO THE AIRWAYS OF THE PATIENT A URIDINE PHOSPHATE SUCH AS URIDINE 5'TRIPHOSPHATE OR DI(URIDINE5') TETRAPHOSPHATE FOR PROMOTING DRAINAGE OF MUCOUS SECRETIONS IN THE CONGESTED AIRWAYS OF A BEDRIDDEN/IMMOBILIZED PATIENT | INSPIRE PHARMACEUTICALS, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6696425-B2 | STIMULATING TEAR SECRETION AND MUCIN PRODUCTION IN EYES OF A SUBJECT BY ADMINISTERING CERTAIN URIDINE, ADENINE, OR CYTIDINE TRIPHOSPHATES AS WELL AS OTHER DINUCLEOSIDE POLYPHOSPHATE COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030186927-A1 | Ectocornea extension promoters | MERCK SHARP & DOHME LLC | 2003-10-02 | — | — | US | disclosed |
| EP-0938322-B1 | USE OF URIDINE TRIPHOSPHATE RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6624150-B2 | Regulating mucus or mucin secretions, bicarbonate secretion or fluid transport in the gastrointestinal tract of a mammal; treating GERD | INSPIRE PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| JP-2003160491-A | DIURIDINE PHOSPHATE-CONTAINING EYE DROP | SANTEN PHARMACEUT CO LTD | 2003-06-03 | — | — | JP | disclosed |
| CN-1406586-A | Eye drop containing diuridine phosphoric acid | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-04-02 | — | — | CN | disclosed |
| EP-1087777-B1 | THERAPEUTIC DINUCLEOTIDE AND DERIVATIVES | INSPIRE PHARMACEUTICALS INC (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2003000056-A1 | JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020193340-A1 | Method of treating dry eye disease with purinergic receptor agonists | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | disclosed |
| EP-1261323-A2 | METHOD OF TREATING GASTROINTESTINAL TRACT DISEASE WITH PURINERGIC RECEPTOR AGONISTS | Inspire Pharmaceuticals, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020155150-A1 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6462028-B2 | P2Y2 AND/OR P2Y4 PURINERGIC RECEPTOR AGONISTS E.G., NUCLEOTIDES OF ADENOSINE, CYTIDINE AND URIDINE, DINUCLEOTIDES AND ANALOGS; TREATING VAGINAL DRYNESS ASSOCIATED WITH MENOPAUSE, CHEMOTHERAPY, AND DISEASES; VULVAR PAIN | INSPIRE PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020128267-A1 | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020052336-A1 | Method of treating gastrointestinal tract disease with purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020013289-A1 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | MERCK SHARP & DOHME CORP. | 2002-01-31 | — | — | US | disclosed |
| US-6323187-B1 | ENHANCE SECRETION CLEARANCE AND CILIARY BEAT FREQUENCY IN MAMMALS; TREATING RESPIRATORY SYSTEM DISORDERS | INSPIRE PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0939637-A4 | METHOD OF TREATING SINUSITIS WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS INC (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1133304-A2 | USE OF NUCLEOTIDES AND DINUCLEOTIDES FOR THETREATMENT OF VAGINAL DRYNESS AND VULVAR PAIN | Inspire Pharmaceuticals, Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001045691-A2 | METHOD OF TREATING GASTROINTESTINAL TRACT DISEASE WITH PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1087777-A2 | THERAPEUTIC DINUCLEOTIDE AND DERIVATIVES | Inspire Pharmaceuticals, Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000030629-A2 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | INSPIRE PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-1999061012-A2 | THERAPEUTIC DINUCLEOTIDE AND DERIVATIVES | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5981506-A | Method for treating sinusitis with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5972904-A | Method of treating sinusitis with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5958897-A | Method of treating sinusitis with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0939637-A1 | METHOD OF TREATING SINUSITIS WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | Inspire Pharmaceuticals, Inc. (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0938322-A2 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | Inspire Pharmaceuticals, Inc. (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5789391-A | Method of treating sinusitis with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5763447-A | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds | INSPIRE PHARMACEUTICALS (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1998003182-A2 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003182-A2 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003177-A1 | METHOD OF TREATING SINUSITIS WITH URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (21 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786526-B2 | Aqueous ophthalmic solution | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY6 437/4885P2RY4 1118/4885 |
| US-20020193340-A1 | Method of treating dry eye disease with purinergic receptor agonists | P2RY1, P2RY12, P2RY2 | P2RY2 3/4885P2RY6 11/4885P2RY4 5/4885 |
| US-20020052336-A1 | Method of treating gastrointestinal tract disease with purinergic receptor agonists | P2RY1, P2RY4, P2RX5 | P2RY2 4/4885P2RY6 8/4885P2RY4 2/4885 |
| US-10632139-B2 | Ophthalmic solution comprising diquafosol | FANCF, UACA, O60361 | P2RY2 361/4885P2RY6 172/4885P2RY4 456/4885 |
| US-20080214490-A1 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | P2RY4, P2RY2, P2RY1 | P2RY2 2/4885P2RY6 13/4885P2RY4 1/4885 |
| US-20050009778-A1 | Method for treating retinal degeneration with purinergic receptor agonists | P2RY1, P2RY6, P2RY2 | P2RY2 3/4885P2RY6 2/4885P2RY4 7/4885 |
| US-20020155150-A1 | USE OF URIDINE TRIPHOSPHATES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF PNEUMONIA IN IMMOBILIZED PATIENTS | UMPS, UPP1, P2RY1 | P2RY2 16/4885P2RY6 13/4885P2RY4 4/4885 |
| US-20150072951-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | FANCF, UACA, O60361 | P2RY2 361/4885P2RY6 172/4885P2RY4 456/4885 |
| US-20020103157-A1 | Method of treating dry eye disease with purinergic receptor agonists | P2RX5, P2RY1, ADORA2A | P2RY2 8/4885P2RY6 12/4885P2RY4 9/4885 |
| US-20140221306-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL, METHOD FOR PRODUCING THE SAME, AND METHOD FOR INHIBITING FORMATION OF INSOLUBLE PRECIPITATE | UACA, QDPR, PRPF6 | P2RY2 999/4885P2RY6 466/4885P2RY4 1708/4885 |
| US-20180353531-A1 | OPHTHALMIC SOLUTION COMPRISING DIQUAFOSOL | FANCF, UACA, O60361 | P2RY2 361/4885P2RY6 172/4885P2RY4 456/4885 |
| US-20190209599-A1 | AQUEOUS OPHTHALMIC SOLUTION | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY6 437/4885P2RY4 1118/4885 |
| US-20060009415-A1 | Corneal epithelial migration promoter | GPR17, UMPS, P2RY6 | P2RY2 7/4885P2RY6 3/4885P2RY4 6/4885 |
| US-20030186927-A1 | Ectocornea extension promoters | GPR17, P2RY13, ENTPD8 | P2RY2 16/4885P2RY6 12/4885P2RY4 13/4885 |
| US-20170348344-A1 | AQUEOUS OPHTHALMIC SOLUTION | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY6 437/4885P2RY4 1118/4885 |
| US-20020013289-A1 | METHOD OF PROMOTING CERVICAL AND VAGINAL SECRETIONS | P2RY4, P2RY2, P2RY1 | P2RY2 2/4885P2RY6 12/4885P2RY4 1/4885 |
| US-10278985-B2 | Aqueous ophthalmic solution | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY6 437/4885P2RY4 1118/4885 |
| US-20020128267-A1 | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | PTGS2, PTGES2, PTGS1 | P2RY2 86/4885P2RY6 344/4885P2RY4 562/4885 |
| US-20020065244-A1 | Method of treating dry eye disease with purinergic receptor agonists | P2RX5, P2RY1, ADORA2A | P2RY2 8/4885P2RY6 12/4885P2RY4 9/4885 |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | P2RY1, P2RY2, P2RY6 | P2RY2 2/4885P2RY6 3/4885P2RY4 5/4885 |
| US-20040058926-A1 | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders | PTGS2, PTGES2, PTGS1 | P2RY2 86/4885P2RY6 344/4885P2RY4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.